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Abstract
Background: Novel immunotherapies, or checkpoint inhibitors, targeting programmed cell death protein-1 (PD-1)
and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) have significantly improved outcomes for patients with
numerous different cancer types. However, owing to their exclusion from clinical trials and risk for autoimmune
exacerbation on these treatments, the impact on safety and degree of toxicity of these potentially life-prolonging
therapies is not well characterized in patients with an underlying autoimmune disease or previous organ transplant.
Case presentation: We report a case of a patient with advanced melanoma and refractory Crohn’s disease who
was treated concurrently with pembrolizumab (anti-PD-1 antibody) and tocilizumab (anti-interluekin-6 receptor
antibody). This novel treatment strategy was well tolerated and did not result in Crohn’s disease exacerbation for at
least 16 weeks. Importantly, this treatment resulted in marked, durable antitumor responses.
Conclusions: This outcome suggests that targeted immunosuppression combined with checkpoint inhibitors may
hold promise as a treatment strategy for this unique patient population and may warrant additional study.
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Background
Checkpoint inhibitor (CPI) therapies targeting PD-1 and
CTLA-4 have improved survival in patients with metastatic
melanoma [1]. Immune-related adverse events (irAEs) are
the most common toxicity associated with CPI therapies.
IrAEs can affect any organ and result from immune dys-
regulation targeting normal tissue. Resultantly, patients
with pre-existing autoimmunity are routinely excluded
from CPI clinical trials for fear of exacerbating their under-
lying autoimmune condition and have limited treatment
options. A notable, recently reported small retrospective
review of 30 patients with pre-existing autoimmunity and
advanced melanoma treated with ipilimumab (anti-CTLA-
4 antibody) demonstrated that 27 % developed an auto-
immune exacerbation and 33 % developed conventional
grade 3–5 irAEs [2] including death. In specific relevance
to this case, six of those patients had inflammatory bowel
disease and two of them experienced a grade 3–5 irAE.
Therefore, determining how to safely deliver immunother-
apies to this unique population without exacerbating their
autoimmune condition poses a significant clinical chal-
lenge and remains an unmet medical need.
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Previous studies report Th-17, a helper T cell subset that
releases interleukin-17 (IL-17), as a key mediator of many
autoimmune diseases, including inflammatory bowel dis-
ease and CPI-induced colitis [3–5]. Importantly, IL-6 plays
an essential role in inducing Th-17 from naïve CD4+ T
cells [6]. Because of this, there has been recent interest in
targeting this differentiated T cell pathway as novel ther-
apy for autoimmunity [3]. In addition, IL-6 blockade has
shown efficacy in reversing cytokine release syndrome, a
clinical by-product of excessive immune activation seen
with adoptive T cell therapies [7, 8], and has also shown
preliminary efficacy against Crohn’s disease in an early
pilot trial [9]. Here, we report a case in which pembrolizu-
mab (anti-PD-1 antibody) was co-administered with toci-
lizumab, an anti-IL-6 receptor antibody that is FDA-
approved for the treatment of rheumatoid arthritis, juven-
ile idiopathic arthritis, and polyarticular juvenile rheuma-
toid arthritis, in a patient with concomitant advanced
melanoma and refractory Crohn’s disease. The patient
showed a significant, durable antitumor response with
limited Crohn’s disease exacerbation. This suggests that
anti-PD-1 therapies, when combined with selective im-
mune inhibitors, can have clinical benefit while possibly
delaying autoimmune exacerbation in patients with con-
current advanced melanoma and Crohn’s disease.
Case presentation
A 49-year-old woman with history of severe, refractory
Crohn’s disease was diagnosed with stage IIA cutaneous
left shoulder melanoma (Breslow thickness 2.8 mm
without ulceration) in 2013. She previously had experi-
enced multiple Crohn’s-related fistulas and required
anti-TNF alpha therapy. She underwent wide local exci-
sion with sentinel lymph node biopsy showing no
residual melanoma and was then placed on surveillance.
In January 2015, she developed multiple extremity skin
nodules and presented to our center. On presentation,
her Crohn’s disease was managed with immunosuppres-
sive therapy including 6-mercaptopurine and low-dose
oral prednisone. Her Crohn’s disease was under moder-
ate control and she experienced only mild diarrheal
symptoms. Biopsies confirmed metastatic melanoma and
mutational analyses revealed wild-type BRAF, NRAS, and
c-KIT. Staging evaluation revealed multiple brain, liver,
and lung metastases. She underwent stereotactic brain
radiosurgery and initiated chemotherapy. Frontline anti-
PD-1 or anti-CTLA-4 therapies were not chosen over
concerns about exacerbating her Crohn’s disease (anti-
PD-1 therapies are notably associated with Th-17 induc-
tion [10]). In May 2015, restaging imaging showed pro-
gressive brain and multi-organ metastases after receiving
two cycles of chemotherapy.
She then initiated whole brain radiotherapy immediately
followed by concurrent pembrolizumab (administered IV
at 2 mg/kg every 21 days) and tocilizumab (administered
IV at 8 mg/kg IV every 21 days) in July 2015 after discon-
tinuing her previous immunosuppressive regimen. Anti-
TNF agents and corticosteroids were avoided over con-
cerns about possibly abrogating the anti-tumor response
to anti-PD-1 agents, a phenomenon seen in a previous
clinical trial that evaluated ipilimumab and corticosteroids
in patients with metastatic melanoma to the brain [11].
After two treatment doses, significant anti-tumor re-
sponses were seen in the brain, liver, lung, and subcutane-
ous lesions without clinical evidence of Crohn’s disease
exacerbation. Peripheral blood analysis demonstrated an
expected increase in IL-6 but without a significant in-
crease in IL-17, suggesting possible suppression of Th-17
induction (Fig. 1). Interestingly, tocilizumab did not
Fig. 1 Correlative immune studies showing cytokine levels (measured in pg/ml) in peripheral blood at specific time points with combination
therapy involving pembrolizumab and tocilizumab
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inhibit the effector CD4+ or CD8+ T cells as demonstrated
by immune phenotyping.
Sixteen weeks after initiating therapy, she presented
with an intra-abdominal abscess requiring drainage and
antibiotics. We discontinued pembrolizumab and
tocilizumab over concerns for possible Crohn’s disease
exacerbation and initiated adalimumab, an anti-TNF
monoclonal antibody. She subsequently recovered un-
eventfully. In January 2016, despite being off systemic
therapy for 3 months, restaging evaluation showed near
complete response of all metastatic sites, including the
brain (Fig. 2). Pembrolizumab was then re-started along
with concurrent adalimumab and her most recent im-
aging in March 2016 showed complete response to
therapy.
Discussion
As a tertiary cancer center, we routinely receive clinically
challenging referrals—the patient described in this case
report is a salient example of this. Our case illustrates
that the strategy of co-administering pembrolizumab
with an agent specifically targeting the IL-6 - Th-17 -
IL-17 pathway, in this case, tocilizumab, in a patient
with advanced melanoma and Crohn’s disease may result
in significant anti-tumor effects while possibly prevent-
ing/delaying autoimmune consequences. Additionally,
for our patient, this combination was well tolerated for
at least 16 weeks with limited signs or symptoms of
Crohn’s exacerbation (i.e., diarrhea, fevers, and abdom-
inal pain).
The patient’s peripheral blood analysis demonstrated
that combination therapy resulted in an expected in-
crease in IL-6 levels. This finding was previously re-
ported in a study of adult patients with rheumatoid
arthritis or Castleman’s disease who received tocilizumab
and is thought to result from decreased IL-6R consump-
tion of IL-6 [12]. However, what is more intriguing is
that there was a little change in IL-17 levels, which again
suggests that there was a limitation of Th-17 induction
as they are the major producers of IL-17 (Fig. 1). Con-
sidering their documented role in both irAEs and
Crohn’s disease pathogenesis [5], blocking Th-17 induc-
tion with tocilizumab could be one possible explanation
as to why our patient demonstrated delayed exacerba-
tion of her underlying Crohn’s disease. Of course, add-
itional studies are needed to confirm this finding.
Furthermore, targeting specific aspects of the immune
response with this strategy has other significant conse-
quences. It is important to note, for example, that Th-17
cells have been shown to be resistant to glucocorticoids,
which may explain why some patients who develop
irAEs or autoimmune exacerbation do not respond to
corticosteroids [13]. Therefore, a strategy which specific-
ally focuses on preventing Th-17 cell induction may di-
minish the need for broad immune suppression with
corticosteroids. As mentioned, using corticosteroids to
treat immune toxicities may also abrogate the anti-
tumor effects of CPI therapies, making their use possibly
detrimental for patients who develop these side effects
[11].
Recently, numerous studies have focused on targeting
this immune pathway in the treatment of autoimmune
diseases. Interleukin-17A inhibitors have been studied in
large clinical trials in plaque psoriasis and ankylosing
spondylitis. In fact, secukinumab and ixekizumab, both
IL-17A antibodies, have been FDA-approved for the
treatment of plaque psoriasis based on phase 3 trials
[14, 15]. Whether or not these agents have a role in
treating patients with autoimmunity and concurrent
cancer has yet to be determined.
Conclusions
This case illustrates that co-administration of anti-PD-1
with anti-IL-6R in patients with advanced melanoma
Fig. 2 Pre- and post-treatment MRI findings showing near complete response to combination therapy with pembrolizumab and tocilizumab. Not-
ably, the patient initially had 18 intracranial metastases that were completely resolved
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and Crohn’s disease can be well tolerated and may at-
tenuate or delay autoimmune exacerbation without
impacting a positive anti-tumor effects. Because this is a
report of one patient only, the results described are
purely descriptive and we are unable to draw any defini-
tive conclusions about the impact of this intervention on
disease-specific outcomes. In summary, the IL-6 - Th-17
- IL-17 pathway may play a pathogenic role in mediating
the irAEs and/or autoimmune exacerbations of patients
with an underlying autoimmune disease treated with im-
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